On April 16, 2022, the Groundbreaking Ceremony of Haichang Biotech’s Innovative Nucleic Acid Drug Manufacturing Base, Ribbon-cutting Ceremony for the Establishment of Nucleic Acid Medicine Innovation Center (NAMIC) and Roundtable Forum On The Cooperation In Nucleic Acid Innovation were held successfully.
.png)
At 9: 00 a.m., the Groundbreaking Ceremony of the Innovative Nucleic Acid Drug Manufacturing Base by Zhejing Haichang Biotech Co., Ltd was successfully held at Hangzhou Biopharma Town. Zhao Xiaobin, president of Haichang Biotech, and leaders including Shao Yuanchang, deputy director of Zhejiang Medical Products Administration, Lu Jianjun, deputy secretary of the Party Working Committee of the Biopharma Town Management Committee and director of the management office, as well as guests from construction supervising units such as Zhejiang
Construction Engineering Group, guests from cooperative enterprises such as Zhejiang University, Kexing Biopharma, Nugene Biopharma, LotusLake Biomedical, Innoforce, and guests from cooperative banks such as China CITIC Bank and Bank of Hangzhou attended the commencement ceremony.
.png)
.png)
With a total investment of RMB 670 million in this project, the total planned construction area measures 72,509 square meters, with a prioritized focus on the R&D and production of innovative nucleic acid drugs. A cGMP manufacturing base in line with the proper standards in China, Unites States and Europe is planned to be built in the Phase I of the project, which will deliver an annual output of 4 million doses of mRNA vaccines. The construction of the project will be completed and put into use in 2023, mainly to facilitate the transformation of the company's R&D results from independent innovation work together with their commercial production and contribute to the company’s status as an international pharmaceutical enterprise integrating R&D, production and sales of drug products.
Ribbon-cutting Ceremony for the Establishment of Nucleic Acid Medicine Innovation Center (NAMIC)
Later, Haichang Biotech held a roundtable forum on the cooperation in nucleic acid innovation at the Hangzhou Double Tree Hotel by Hilton. Professor Gu Zhen, dean of College of Pharmaceutical Sciences, Zhejiang University, Professor Chen Shuqing, president of Hangzhou Neoantigen Biotechnology Co., Ltd., Liu Bing, vice president of operations of Beijing Lotus Lake Biomedical Technology Co., Ltd., and Zhao Xiaobin, President of Zhejing Haichang Biotech Co., Ltd., gave reports and expressed their insights on the opportunities and challenges in China’s mRNA industry development, research status of neoantigen mRNA vaccine, cell and gene therapy technologies etc. The seminar has set up a properly functional platform for sufficiently extensive communications and exchanges on the industry-university-research cooperation in the field of nucleic acid innovation.
Later, Haichang Biotech held a roundtable forum on the cooperation in nucleic acid innovation at the Hangzhou Double Tree Hotel by Hilton. Professor Gu Zhen, dean of College of Pharmaceutical Sciences, Zhejiang University, Professor Chen Shuqing, president of Hangzhou Neoantigen Biotechnology Co., Ltd., Liu Bing, vice president of operations of Beijing Lotus Lake Biomedical Technology Co., Ltd., and Zhao Xiaobin, President of Zhejing Haichang Biotech Co., Ltd., gave reports and expressed their insights on the opportunities and challenges in China’s mRNA industry development, research status of neoantigen mRNA vaccine, cell and gene therapy technologies etc. The seminar has set up a properly functional platform for sufficiently extensive communications and exchanges on the industry-university-research cooperation in the field of nucleic acid innovation.
